Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00
Provider: Wright Reports
$460.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mauna Kea Technologies SA Announces First Use of Optical Biopsy with Cellvizio in Robotic Assisted Prostatectomy


Tuesday, 5 Nov 2013 11:45am EST 

Mauna Kea Technologies SA announced that Joseph C. Liao MD, associate professor of urology, Stanford University, has successfully used endomicroscopy with Cellvizio for the first time in eight patients treated with robotic assisted radical prostatectomy (RARP) procedures. Results were presented in a poster presentation at the 2013 World Congress of Endourology Meeting in New Orleans. In the feasibility study the use of endomicroscopy with Cellvizio was shown to provide real time imaging of prostate and surrounding tissues during RARP procedures using the da Vinci Surgical System. Intraoperative probe-based confocal laser endomicroscopy (pCLE) also known as optical biopsy was successfully performed in eight patients with no related complications. According to the study results, optical biopsy with Cellvizio was shown to enable stable microscopic visualization of a range of important surgical and oncologic landmarks including neurovascular bundles, which could help surgeons identify optimal nerve-sparing techniques for RARP. 

Company Quote

6.2
-0.2 -3.13%
24 Jul 2014